Etripamil is under clinical development by Milestone Pharmaceuticals and currently in Pre-Registration for Supraventricular Tachycardia. According to GlobalData, Pre-Registration drugs for Supraventricular Tachycardia have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Etripamil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Etripamil overview

Etripamil (MSP-2017) is under development for the treatment of transient cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT), and atrial fibrillation. The drug candidate is a short-acting therapeutic administered by intranasal route as a spray. It is a new chemical entity and acts by targeting calcium channel.

It was under development for stable angina.

Milestone Pharmaceuticals overview

Milestone Pharmaceuticals is a Pharmaceutical company. It develops novel small molecule therapeutics. The company undertakes the development of small molecule therapeutics based on clinically validated mechanisms, for the treatment of cardiovascular diseases. It’s lead product etripamil, is a potent short-acting calcium channel antagonist for the systemic treatment of cardiovascular conditions such as angina, paroxysmal supraventricular tachycardia and atrial arrhythmias. It offers products through nasal sprays for the provision of rapid systemic drug delivery that can be used by electrocardiogram (ECG)-diagnosed patient. It operates in the US and Canada. Milestone Pharmaceuticals is headquartered in Saint-Laurent, Quebec, Canada.

For a complete picture of Etripamil’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.